Pacira biosciences, inc. (PCRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

105,684

-

-

-

91,313

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative licensing and milestone revenue

-

-

0

0

-

-

0

3,000

-

25

26

130

206

357

1,357

1,356

356

357

357

356

356

1,287

357

322

252

243

243

243

243

1,816

3,484

6,600

6,490

1,229

1,352

1,283

1,210

765

819

Total revenues

-

-

104,685

102,604

-

95,115

83,448

84,107

74,607

79,078

67,335

70,934

69,283

72,902

68,355

69,640

65,474

69,320

62,213

59,148

58,316

197,668

52,048

47,165

36,662

33,564

23,259

17,141

11,587

10,450

8,486

12,344

7,804

4,234

3,956

3,636

3,863

4,532

3,055

Operating expenses:
Cost of goods sold

29,732

31,904

22,304

25,201

27,303

23,979

19,065

20,916

22,885

21,295

18,228

23,811

24,581

23,621

43,152

23,053

20,278

19,427

15,901

18,929

17,580

77,440

20,391

19,954

18,127

18,376

14,791

10,214

11,391

9,672

9,287

6,685

6,495

6,600

3,357

3,115

3,667

3,573

2,849

Research and development

15,819

19,653

20,255

17,827

14,384

14,174

14,897

12,239

14,378

10,027

11,775

18,856

16,632

17,069

9,754

9,362

9,493

13,153

5,893

3,649

5,967

18,731

4,425

5,216

5,204

4,836

5,962

4,857

5,905

3,244

3,527

1,872

1,294

2,132

4,360

4,586

3,795

5,716

4,596

Selling, general and administrative

44,780

54,223

50,128

49,126

47,305

44,646

44,179

44,249

44,191

39,178

40,644

39,552

42,120

34,673

36,314

43,669

37,957

37,553

35,310

34,752

31,428

106,662

28,217

24,837

22,589

20,172

15,320

14,080

12,936

13,363

11,378

10,413

11,152

7,198

4,972

4,466

3,523

1,694

1,238

Amortization of acquired intangible assets

2,000

1,900

2,000

1,800

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition-related charges, product discontinuation and other

3,708

37,495

-7,618

-3,405

-1,242

3,075

-1,259

-162

-90

9,623

-260

-4,495

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

88,590

-

-

-

90,234

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

102,272

97,329

-

82,852

79,400

77,566

81,544

70,613

70,907

86,714

83,333

75,363

89,220

76,084

67,728

70,133

57,104

57,330

54,975

202,833

53,033

50,007

45,920

43,384

36,073

29,151

30,232

26,279

24,192

18,970

18,941

18,949

12,689

12,167

10,985

10,983

8,683

Income from operations

17,094

1,713

2,413

5,275

1,079

12,263

4,048

6,541

-6,937

8,465

-3,572

-15,780

-14,050

-2,461

-20,865

-6,444

-2,254

-813

5,109

1,818

3,341

-5,165

-985

-2,842

-9,258

-9,820

-12,814

-12,010

-18,645

-15,829

-15,706

-6,626

-11,137

-14,715

-8,733

-8,531

-7,122

-6,451

-5,628

Other (expense) income:
Interest income

1,589

1,667

1,736

1,817

2,156

2,004

1,586

1,533

1,374

1,272

1,068

1,224

514

401

346

324

252

175

171

177

155

382

134

61

42

52

62

72

73

57

87

68

63

143

46

37

29

39

38

Interest expense

6,022

5,996

5,940

5,878

5,814

5,753

5,642

5,397

5,157

5,105

5,127

5,226

2,589

1,859

1,601

1,733

1,868

1,884

1,905

1,940

1,996

8,278

2,037

2,079

2,107

1,928

1,892

1,914

1,519

343

456

494

514

713

910

676

2,481

1,077

887

Loss on early extinguishment of debt

-

-

-

-

-

-

-

-

-

0

0

-11

-3,721

0

0

0

0

-

0

-51

-

0

0

0

-

0

0

0

-3,398

-

0

-1,062

-

-

-

-

-

-

-

Royalty interest obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

71

323

73

136

120

244

132

161

86

231

-378

143

282

7

-116

-429

311

444

433

Other, net

-4,104

-925

-4,025

-87

61

-191

-694

-78

75

-2

79

80

10

-75

-8

-47

48

-83

-8

43

-117

-159

-43

-41

-34

-16

-8

-18

-5

0

-48

-39

-24

10

-27

-22

110

33

97

Total other expense, net

-8,537

-5,254

-8,229

-4,148

-3,597

-3,940

-4,750

-3,942

-3,708

-3,835

-3,980

-3,933

-5,786

-1,533

-1,263

-1,456

-1,568

-1,793

-1,742

-1,771

-2,029

-8,378

-2,019

-2,195

-2,219

-2,136

-1,970

-2,021

-4,935

-517

-39

-1,670

-757

-567

-775

-232

-2,653

-1,449

-1,185

Income (loss) before income taxes

8,557

-3,541

-5,816

1,127

-2,518

8,323

-702

2,599

-10,645

4,630

-7,552

-19,713

-19,836

-3,994

-22,128

-7,900

-3,822

-2,606

3,367

47

1,312

-13,543

-3,004

-5,037

-11,477

-11,956

-14,784

-14,031

-23,580

-16,346

-15,745

-8,296

-11,894

-

-

-

-

-

-

Income tax expense

400

1,315

300

-1,600

253

38

-62

35

35

35

45

30

30

-21

36

58

32

-108

281

39

52

173

0

0

0

0

0

0

-442

-

0

-

-

-

-

-

-

-

-

Net income (loss)

8,159

-4,888

-6,087

2,730

-2,771

8,285

-640

2,564

-10,680

4,595

-7,597

-19,743

-19,866

-3,973

-22,164

-7,958

-3,854

-2,498

3,086

8

1,260

-13,716

-3,004

-5,037

-11,477

-11,956

-14,784

-14,031

-23,138

-16,346

-15,745

-8,296

-11,894

-15,282

-9,508

-8,763

-9,775

-7,900

-6,813

Net income (loss) per share:
Basic and diluted net income (loss) per common share (in USD per share)

0.19

-

-0.15

-

-0.07

-

-0.02

-

-0.26

0.13

-0.19

-0.49

-0.52

-0.12

-0.59

-0.21

-0.10

-

-

0.00

0.03

-

-

-0.14

-0.34

-

-0.44

-0.42

-0.71

-0.49

-0.49

-0.27

-0.47

-0.60

-0.55

-0.51

-0.98

-13.77

-11.86

Basic net income (loss) per common share (in USD per share)

-

-

-

0.07

-

-

-

0.06

-

-

-

-

-

-

-

-

-

-

0.08

-

-

-0.39

-0.08

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss per common share (in USD per share)

-

-

-

0.06

-

-

-

0.06

-

-

-

-

-

-

-

-

-

-

0.08

-

-

-0.39

-0.08

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding:
Basic and diluted (in shares)

42,032

41,783

41,645

41,384

41,240

41,146

40,995

40,796

40,707

40,603

40,463

40,160

37,998

37,431

37,312

37,181

37,020

36,781

36,663

36,481

36,235

35,299

35,943

35,463

33,711

33,575

33,360

33,083

32,709

32,570

32,436

30,953

25,367

21,271

17,230

17,233

10,014

573

-

Diluted (in shares)

42,785

-

-

42,345

41,240

-

-

41,694

-

-

-

40,160

-

-

-

-

-

40,937

41,043

41,445

41,779

35,299

35,943

35,463

33,711

-

-

-

-

-

-

-

-

-

-

-

10,014

573

-

Basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

574

Product
Total revenues

104,745

121,846

104,350

101,824

90,906

94,715

82,708

80,717

74,287

78,827

66,951

70,139

68,425

71,765

66,119

67,687

64,502

68,189

61,150

58,062

57,086

193,526

50,920

46,034

35,742

32,435

22,408

16,278

10,835

8,214

4,550

4,981

446

1,091

1,682

1,469

2,653

2,744

1,460

Royalty
Total revenues

939

578

335

780

407

400

740

390

320

226

358

665

652

780

879

597

616

774

706

730

874

2,855

771

809

668

886

608

620

509

420

452

763

868

-

922

884

-

1,023

776